NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

199.71B

Vuru Grade

66.54/100

Current Price

$85.24
-0.99 (-1.15%)

Growth Price

$51.84
Overvalued by 39.19%

Stability Price

$17.18
Overvalued by 79.84%

Company Metrics

  • P/E 31.12
  • P/S 4.11
  • P/B 2.89
  • EPS 2.74
  • Cash ROIC 10.35%
  • Cash Ratio 0.35
  • Dividend 2.72 / 3.20 %
  • Avg. Vol. 1.69M
  • Shares 2.34B
  • Market Cap. 199.71B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

3 Stocks to Watch on Tuesday: Boeing Co (BA), McDonald's Corporation (MCD) and ...
Investorplace.com - Sep 5, 2017
No investing took place yesterday due to Labor Day, which saw gasoline prices decline in the country. U.S. crude prices were mixed as several refineries were back in action as Hurricane Harvey exited most of the affected regions in Texas.
​Here's The Real Importance Of The Latest Novartis AG (ADR) (NYSE:NVS) News
Equities.com - Sep 5, 2017
Novartis AG (ADR)(NVS) just announced that the Food and Drug Administration (FDA) in the US has approved one of its lead oncology development assets, a drug called Kymriah (CTL019), in a target indication of patients up to 25 years of age with B-cell ...
Novartis Wins FDA Approval for Groundbreaking Cancer Gene Therapy
Investorplace.com - Aug 30, 2017
The Food and Drug Administration (FDA) has approved the latest Novartis AG (ADR) (NYSE:NVS) cancer treatment. FDA The drug is considered a groundbreaking approach to treating the deadly illness and it is called CAR-T, consisting of advanced gene ...
Novartis Lower Despite FDA Approval For Treatment Of Leukemia - Benzinga
$1.25 EPS Expected for Novartis AG (ADR) (NVS)
WeeklyHub - 10 hours ago
Analysts expect Novartis AG (ADR) (NYSE:NVS) to report $1.25 EPS on October, 24 before the open.They anticipate $0.02 EPS change or 1.63 % from last quarter's $1.23 EPS.
Analysts See $1.25 EPS for Novartis AG (ADR) (NVS) - Finance News Daily
Novartis AG (ADR) (NVS) EPS Estimated At $1.25 - KL Daily
EPS for Novartis AG (ADR) (NVS) Expected At $1.25; Hsbc Holdings Plc Boosted ...
UtahHerald.com - Sep 22, 2017
Analysts expect Novartis AG (ADR) (NYSE:NVS) to report $1.25 EPS on October, 24 before the open.They anticipate $0.02 EPS change or 1.63% from last quarter's $1.23 EPS.
As Novartis Ag Adr (NVS) Market Valuation Rose, Country Trust Bank Boosted by ... - BZ Weekly
Novartis Ag Sponsored Adr (NVS) Stake Increased by Cambridge Trust Company - Weekly Register
Biotech Movers: Novartis AG (ADR) (NYSE:NVS), Otonomy, Inc. (NASDAQ:OTIC)
Market Exclusive - Aug 31, 2017
The first bit of news out of the market today in the biotechnology space is rooted in an approval just announced by biotechnology behemoth Novartis AG (ADR) (NYSE:NVS). The company announced on Wednesday that a drug called Kymriah (CTL019) ...
Wilkins Investment Counsel Increased Novartis Ag (Adr) (NVS) Holding By ... - UtahHerald.com
Can analysts adopt a bullish outlook for Novartis AG (ADR) (NYSE:NVS)? - Finance News Daily
Are Analysts Bearish Novartis AG (ADR) (NYSE:NVS) After Last Week?
WeeklyHub - Sep 18, 2017
Among 15 analysts covering Novartis Ag (NYSE:NVS), 5 have Buy rating, 2 Sell and 8 Hold. Therefore 33% are positive. Novartis Ag had 30 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Buy” rating by Argus Research given on ...
Novartis Ag (NVS) Stake Has Upped by Foyston Gordon & Payne Inc - Finance News Daily
Nelson Roberts Investment Advisors Has Decreased Its Novartis AG Spon Adr (NVS ... - FlintDaily.com
Davis Selected Advisers Upped Novartis Ag Adr (NVS) Holding By $4.49 Million ...
Key Gazette - Sep 24, 2017
Davis Selected Advisers increased Novartis Ag Adr (NVS) stake by 18.11% reported in 2017Q2 SEC filing. Davis Selected Advisers acquired 54,110 shares as Novartis Ag Adr (NVS)'s stock rose 4.17%. The Davis Selected Advisers holds 352,820 shares with ...
$1.25 EPS Expected for Novartis AG (ADR) (NVS); 6 Analysts Covering 8Point3 ...
MoneyMakingArticles - Sep 24, 2017
Analysts expect Novartis AG (ADR) (NYSE:NVS) to report $1.25 EPS on October, 24 before the open.They anticipate $0.02 EPS change or 1.63% from last quarter's $1.23 EPS.
Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade
Investorplace.com - Sep 21, 2017
Novartis AG (ADR) (NYSE:NVS) recently secured the first-ever FDA approval for a CAR-T cancer therapy. As much and as InvestorPlace's James Brumley thoughtfully detailed earlier this week, the combined actions of Gilead and Novartis are significant for ...
Growth Rate Assumed by Market

We did a reverse valuation to calculate the growth rate the market is assuming for NVS to be considered fairly valued at its current market price. It's useful to compare this to the growth rate we're assuming for the Growth Price.

Future Free Cash Flow Growth Rate

This is the annual growth rate we've applied to calculate NVS's Free Cash Flow for the next 10 years. To calculate it, we looked at several time periods of the last 10 years. Feel free to adjust it, but we limit the initial growth rate to 20% and slow it down over the years. Otherwise, long-term sustainability issues come into play.

Discount Rate

The discount rate is the annual rate of return an investor requires to take the risk of investing in a single stock. To account for that risk, this should be above 8-10%, as this is the avg. annual rate of return for the S&P500 over the past 100 years.

$85.24 Current Price

$51.84 Growth Price (DCF)

Overvalued by 39.19%


Growth Rate Assumed by Market: 20.01%


Future Free Cash Flow Growth Rate: -4.4%


Discount Rate: 15.0%


Show Free Cash Flow numbers

$17.18 Stability Price (EPV)

Overvalued by 79.84%


Discount Rate: 15.0%

$66.24 Book Price

Overvalued by 22.29%


Satisfactory Cash Return on Invested Capital over the past 5 years

NVS has somewhat efficiently invested its financial resources in buildings, projects, and equipment. If CROIC is inconsistent, it's likely NVS could be benefiting from a one-time event or has a mixed history of investing capital productively. Read the company's Annual Report to determine whether this can improve.

NVS has created $10.35 of cash for every $100 invested.
Figures in USD. Fiscal year ends in December
20122013201420152016
Free Cash Flow 11.13B 9.60B 10.49B 8.39B 8.60B
divided by
Invested Capital 92.05B 90.66B 84.55B 104.00B 100.14B
Cash ROIC 12.09% 10.59% 12.41% 8.07% 8.58%

Satisfactory Return on Equity over the past 5 years

NVS has generated adequate returns with capital that shareholders have invested. This is sufficient and implies that management performance has been good.

NVS has generated $14.60 of Earnings for every $100 of Shareholders' Equity.
Figures in USD. Fiscal year ends in December
20122013201420152016
Net Income 9.62B 9.29B 10.28B 17.79B 6.70B
divided by
Stockholders' Equity 69.09B 74.34B 70.77B 77.05B 74.83B
Return on Equity 13.92% 12.50% 14.53% 23.10% 8.95%

Excellent Business Performance over the past 10 years

NVS has been able to maintain profitability in good times and bad. This could mean NVS has an extremely strong business or has the ability to scale down costs when needed. This should be a fairly resilient business, but double check for future sustainability by looking at its Risk Factors in the Annual Report.

NVS has created positive free cash flow for 9 or more of the past 10 years.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Free Cash Flow 13.68B 7.35B 10.30B 12.39B 11.92B 11.13B 9.60B 10.49B 8.39B 8.60B

Good Balance Sheet

NVS's Total Assets double Total Liabilities. Its financial position is adequate. Remember to check Shareholders' Equity to see if it's stable or growing. It's one of the best measures of whether a company is creating value for shareholders.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Cash 8.96B 3.74B 17.45B 8.13B 4.96B 8.12B 9.22B 13.86B 3.85B 7.78B
Current Assets 27.43B 20.88B 33.69B 26.69B 24.08B 28.00B 30.54B 37.56B 22.85B 24.93B
Total Assets 75.45B 78.30B 95.51B 123.32B 117.50B 124.22B 126.25B 125.39B 131.56B 130.12B
Current Liabilities 16.64B 16.50B 19.47B 24.66B 23.15B 24.05B 26.37B 26.97B 23.71B 22.21B
Total Liabilities 26.23B 28.01B 38.12B 60.12B 51.65B 55.12B 51.91B 54.62B 54.51B 55.29B
Stockholder' Equity 49.22B 50.29B 57.39B 63.20B 65.84B 69.09B 74.34B 70.77B 77.05B 74.83B
Current Ratio 1.65 1.27 1.73 1.08 1.04 1.16 1.16 1.39 0.96 1.12
TL-to-TA 0.35 0.36 0.40 0.49 0.44 0.44 0.41 0.44 0.41 0.42

Consistent Reinvestment of Profits over the past 10 years

NVS has consistently retained profits. This may put NVS in a strong position to invest for the future, by buying new machinery, investing in R&D or a number of other options. By effectively using these earnings, NVS can greatly improve their long-term economic picture.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Retained Earnings 45.03B 49.83B 56.56B 62.36B 64.95B 68.18B 73.43B 69.87B 76.16B 81.15B
Retained Earnings Growth - 10.65% 13.52% 10.26% 4.15% 4.98% 7.70% -4.85% 9.00% 6.55%

Competitive Advantage over the past 10 years

NVS likely has a competitive advantage which prevents other companies from entering or competing in their industry. This could be strong branding, the ability to keep costs low, or some other characteristic that is hard to replicate. Look at future prospects to determine its sustainability.

$20.48 of every $100 of Revenue have been pure profit, on average over the past 10 years.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Net Income 11.95B 8.20B 8.45B 9.97B 9.25B 9.62B 9.29B 10.28B 17.79B 6.70B
divided by
Revenue 38.07B 42.58B 45.10B 51.56B 59.38B 57.56B 58.83B 53.63B 50.39B 49.44B
Net Profit Margin 31.38% 19.24% 18.74% 19.33% 15.57% 16.71% 15.79% 19.17% 35.31% 13.55%

Strong Pricing Power over the past 10 years

NVS has maintained substantial gross margins, suggesting that they have been able to set prices without consideration of the cost of goods sold. This potentially leaves flexibility in inflationary environments to raise prices on consumers and maintain profitability.

$68.89 of every $100 worth of sales have been Gross Profit, on average over the past 10 years.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Gross Profit 27.04B 31.15B 32.92B 37.07B 40.39B 38.81B 39.22B 36.29B 32.98B 31.92B
divided by
Revenue 38.07B 42.58B 45.10B 51.56B 59.38B 57.56B 58.83B 53.63B 50.39B 49.44B
Gross Margin 71.02% 73.14% 73.00% 71.90% 68.03% 67.42% 66.67% 67.66% 65.46% 64.56%

Medium Capital Intensity over the past 10 years

NVS has used a reasonable amount of their financial resources to invest in facilities and equipment required to produce its goods and services. This isn't perfect, but it shouldn't be an area of concern unless this number is strongly trending upwards.

28.56% of Profits are being spent on Capital Expenditures, like Property, Plant, & Equipment, required to run the business.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Capital Expenditure 3.13B 2.32B 1.89B 1.68B 2.39B 3.07B 3.57B 3.40B 3.51B 2.88B
divided by
Net Income 11.95B 8.20B 8.45B 9.97B 9.25B 9.62B 9.29B 10.28B 17.79B 6.70B
Capital Expenditure Ratio 26.23% 28.26% 22.32% 16.83% 25.82% 31.90% 38.43% 33.11% 19.70% 42.98%

Very Strong Dividend History over the past 10 years

NVS has consistently distributed a dividend for at least the past 10 years. Such a long dividend history suggests NVS is very established in its market and that its dividend distribution is likely to continue for a significant period of time.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Dividend Paid 2.60B 3.35B 3.99B 4.58B 5.57B 6.12B 6.20B 6.95B 6.65B 6.48B
divided by
Shares Outstanding 2.33B 2.28B 2.27B - 2.41B 2.45B 2.48B 2.43B 2.40B 2.40B
Dividend Paid Per Share 1.12 1.46 1.76 - 2.31 2.50 2.50 2.86 2.77 2.70
Price at Year End 45.10 42.38 48.36 54.10 54.72 62.90 80.34 93.21 87.53 72.84
Dividend Yield 2.47% 3.46% 3.64% - 4.22% 3.98% 3.11% 3.07% 3.16% 3.70%

History of Stock Buybacks over the past 10 years

NVS has some history of delivering increased value for shareholders in the form of stock buybacks. These have helped improve financial metrics and increase each shareholders' relative ownership stake in the company, due to fewer shares outstanding and holding the same number of shares.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Shares Outstanding 2.33B 2.28B 2.27B - 2.41B 2.45B 2.48B 2.43B 2.40B 2.40B
Stock Bought Back - 1.94% 0.72% - -100.00% -1.31% -1.37% 2.18% 0.96% 0.13%
Share your thoughts about NVS

Sign Up or Log In to start contributing!


Discussion
Sort By:
7
Posted by AlwaysAContrarian  (on March 18, 2012)
There are plenty of pharamceuticals that are suffering from expiring patents. Hence, why the whole group of them are undervalued. There’s definitely going to be some corpses. Not sure if NVS will be one of them but they do have a number of promising anti-cancer drugs in the pipeline.
2
Posted by tmuscat27  (on March 23, 2012)
Medical companies always lose patents that is why I go year by year.I look at the eps and the probabilty of achieving the said eps and I discounted ot be on the safe side and by at the safe price
ANOTHER WAY I do it is by multiplying the 10 year average diluted eps bu the signiture eps and discount it.
2
Posted by Honeybadger  (on March 23, 2012)
I personally find eps a poor metric under most circumstances. Eps is easily (and legally) manipulated. Just playing devil's advocate.
1
Posted by timholland  (on March 26, 2012)
I agree (not playing devil's advocate). A much better indicator of company profitability is Free Cash Flow. Much less easily manipulated.
1
Posted by theguy  (on March 23, 2012)
How do you figure out the probability of a company achieving a given eps?
1
Posted by rsarda1  (on March 26, 2012)
What is going to kill the pharmaceuticals is the new ObamaCare. They are going to be even more heavily regulated than now, to the point that even the pricing of the drags will be determine by the Health Care secretary. This will result in less R&D, less new experimental medications, etc... all things that requires big initial spending. It will make much harder to recoup the initial investment. And they will focus on competing for with who makes the best aspiring, Tylenol, or similar.

who cares about aspirin - let the CVS make it - aspirin has been around so long that is hard to messit up.

Say goodbye to the free market competition in the pharmaceutical field.
1
Posted by tmuscat27  (on March 21, 2012)
That 20% was a guess. I know beause I take pills manufactured by nvs and the substitute was about 20%
tm
1
Posted by dougmccormick  (on March 21, 2012)
That assumes NVS's market share only drops 20%. If there's a product sells for 20% less, they could lose significantly more market share than just 20% if you see what I mean.
1
Posted by tmuscat27  (on March 21, 2012)
does anyone have info on azn, I was reading that they like to shed a lot of employees, but I think it is a better company. Any tgoughts?
1
Posted by tmuscat27  (on March 21, 2012)
patents are coming off however nvs has a generic subsidiary, I think the company would still sell the product, so the loss in profits would be around 20%
tm
1
Posted by dougmccormick  (on March 21, 2012)
NVS will definitely still sell the products but when there's a generic drug that's the equivalent selling for 30% less... surely they're going to take a bigger hit than 20%.

Do you have any examples of companies in similar situations who only saw profits drop 20%?
0
Posted by buffettdisciple  (on March 19, 2012)
Limited upside with high risk around expiring patents. I’m steering clear until there’s a more certain future for this stock.